EMA validates BMS’s repotrectinib application to treat cancer
The EMA has validated the marketing authorisation application of Bristol Myers Squibb (BMS) for repotrectinib to treat solid tumours.
The EMA has validated the marketing authorisation application of Bristol Myers Squibb (BMS) for repotrectinib to treat solid tumours.
What's Your Reaction?
